Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy

Acta Ophthalmol. 2008 Sep;86(6):694-5. doi: 10.1111/j.1600-0420.2007.01132.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / etiology
  • Fluorescein Angiography
  • Humans
  • Indocyanine Green
  • Injections
  • Macular Degeneration / complications*
  • Male
  • Pigment Epithelium of Eye / pathology*
  • Ranibizumab
  • Tomography, Optical Coherence
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity
  • Vitreous Body

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Indocyanine Green
  • Ranibizumab